Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
44.50    0.00 (0.00%)
Bid:
44.00
Ask:
45.00
Spread: 1.00 (2.273%)
Market Cap: £81.54m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Q1 2019 Market Update

17 Apr 2019 07:00

RNS Number : 4129W
Iofina PLC
17 April 2019
 

 

17 April 2019

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

Q1 2019 Market Update

 

Year-on-Year iodine production up 14%; iodine prices continue to rise

 

Iofina, specialists in the exploration and production of iodine and manufacturers of other halogen-based derivatives at its specialty chemical company, today provides an update to the market regarding its activities in the first quarter of 2019 ("Q1" or the "Period"), during which the Group increased year-on-year iodine production by 14% and finalised its debt restructuring terms.

At the end of the Period, the Group announced the successful restructuring of its debt. The debt with the Group's long-time Noteholders was extended to July 2020 and the convertibility feature was removed. This is a significant achievement, as it will allow the Group to execute on growth plans in 2019 and beyond.

During the Period, the Company produced 134.4 MT of crystalline iodine, a 14% increase from the same period in 2018 (Q1 2018: 118.2 MT) and the highest level of Q1 iodine production in Company history. A full quarter's production at the Group's newest plant, IO#7, which was commissioned during the first quarter of 2018, was a significant factor in the year-on-year increase in output. The Group is encouraged by how well IO#7 has performed over the Period, and it plans to build more plants with similar productivity over the short term.

As anticipated, the extreme winter weather conditions in Oklahoma in January and February have impacted production efficiencies. Whilst brine water volumes available to the four IOsorb® plants, as well as the levels of iodine concentration, were as expected, the IO#6 plant experienced an out of tolerance fall in efficiencies towards the end of the quarter. The Company is currently focused on IO#6 and is making progress with restoring expected efficiencies. In addition, works planned for IO#4, which would enhance iodine output, have been delayed into Q2 due to resource constraints linked to a high level of activity by our partner. The net effect of these factors means that the Group prudently expects a reduction of approximately 10% to its ambitious H1 2019 production target, detailed on 17 January 2019.

During the Period, Iofina Chemical traded strongly, and exceeded the Group's internal forecasts, as it continues to deliver high quality iodine and specialty chemicals to customers globally.

The global iodine market remains robust and iodine prices have continued to rise into early Q2 2019. Large volume spot sales of iodine at the end of the Period were generally over $28/kg, a 16% rise on last year's spot price (Q1 2018: $24/kg). Iofina expects pricing to continue to move higher in 2019 from these levels.

Commenting, President and CEO Dr. Tom Becker stated: ''I am pleased with the Group's solid start to the year, which has seen us successfully renegotiate the debt terms of our loan. The completion of the debt restructuring is an important achievement as it provides the Group with flexibility to execute on its long-term business strategy. It is also pleasing to report that we have achieved a 14% year-on-year increase in iodine production from our four operating IOsorb® plants. The increase in production, coupled with the continued rise in iodine prices, has positioned Iofina well for a strong 2019.

 

"Whilst we are behind our aggressive production target for H1 2019, we are confident that production output will resume to normal levels once the appropriate works are completed and look forward to higher production levels in Q2 2019 with warmer weather and lower down time."

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Anthony Adams (corporate finance)

Camille Gochez (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7544 275 882

About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

THE INFORMATION COMMUNICATED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUNOKRKBASAAR
Date   Source Headline
5th Jun 20267:00 amRNSAgreement Signed for Additional Brine Water Supply
5th May 20267:00 amRNSNotice of AGM
30th Apr 20264:45 pmRNSHolding(s) in Company
30th Apr 202611:30 amRNSHolding(s) in Company
30th Apr 20267:00 amRNSFinal Results
16th Apr 20261:40 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSQ1 2026 Corporate Update
20th Mar 202612:25 pmRNSHolding(s) in Company
13th Jan 20267:00 amRNSQ4 2025 Corporate Update
6th Jan 20267:00 amRNSHolding(s) in Company
12th Dec 20257:00 amRNSDirectorate change
5th Dec 20257:00 amRNSAgreement with Western Midstream
12th Nov 20258:15 amRNSHolding(s) in Company
16th Oct 20257:00 amRNSQ3 2025 Update
3rd Oct 20253:32 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSBusiness Update
17th Jul 20257:00 amRNSH1 2025 Update
9th Jul 20257:00 amRNSCapital Reduction
9th Jun 20255:00 pmRNSResult of AGM
14th May 20257:00 amRNSNotice of AGM and Proposed Capital Reduction
12th May 20257:00 amRNS-RInvestor Presentation
12th May 20257:00 amRNSFinal Results
25th Apr 20253:45 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 2025 Update
23rd Jan 20257:00 amRNSQ4 2024 Update
18th Dec 20244:45 pmRNSHolding(s) in Company
21st Oct 20247:00 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSQ3 2024 Update
27th Sep 20247:00 amRNSIO#11 Update
20th Sep 20247:00 amRNSInterim Results
13th Sep 20247:00 amRNSIO#10 Iodine Plant Commissioned
16th Jul 20247:00 amRNSH1 Update
27th Jun 202411:04 amRNSHolding(s) in Company
25th Jun 20247:00 amRNSHolding(s) in Company
13th Jun 20241:00 pmRNSResult of AGM
29th May 20244:50 pmRNSLaunch of new website
15th May 20247:00 amRNSNotice of AGM and Resignation of Director
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.